

2022-2023

American Heart Association

Funding from Pharmaceutical and Biotech Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association’s finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau’s Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as revenue from the sale of mission-aligned products and services, such as CPR training, and investment earnings.

Financial support from corporations helps the association’s programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association’s corporate relations policies and are approved by a committee of national volunteers and executive staff.

Total corporate funding is comprised of unrestricted gifts, special event and program sponsorships and fees from program-related services. Corporate funding represents approximately 15.7 percent of the AHA’s \$1.2 billion total revenue.

Funding that the American Heart Association receives from pharmaceutical and biotech companies and device manufacturers is included within total corporate funding and represents approximately 4 percent of the association’s total revenue.

The revenue figures below include the total amount of funds earned or committed to the American Heart Association during fiscal year 2022-2023, noting that, in some cases, the funds will be received in future years. The chart provides funds from pharmaceutical and biotech companies and device manufacturers in proportion to all sources of revenue.



Following is a schedule of corporate funding provided to the American Heart Association from pharmaceutical and biotech companies and medical device manufacturers during fiscal year 2022-2023. The schedule reflects cash received during fiscal year 2022-2023 and revenue committed to the American Heart Association that will be received in future years.

2022-2023 Corporate Funding Received from Pharmaceutical and Biotech Companies and Device Manufacturers		
Corporation	Total Cash Received During 2022- 2023 on Prior and Current Year Commitments (1)	2022-2023 Commitments Receivable in the Future
Abbott	483,100	250,000
Amgen, Inc.	3,190,500	3,000,000
AstraZeneca	2,173,583	2,577,205
AtriCure, Inc.	170,000	40,000
Bayer Healthcare Pharmaceuticals, Inc.	1,061,333	50,000
Biogen	79,390	-
Boehringer Ingelheim	2,590,288	-
Boston Scientific	243,000	-
Bristol Myers Squibb	5,481,676	2,414,431
Cerenovus	73,000	-
CSL Behring	296,500	160,000
Cytokinetics, Incorporated	323,000	-
Edwards Lifesciences	3,132,900	7,500,000
FUJIFILM Diosynth Biotechnologies	57,500	15,000
GlaxoSmithKline	527,590	-
Impulse Dynamics	318,000	-
Ipsen Biopharmaceuticals, Inc.	155,000	-
Jazz Pharmaceuticals, Inc.	875,000	-
Johnson & Johnson	1,172,209	200,000
Kiniksa Pharmaceuticals	474,200	-
Laerdal	2,500	1,700,000
Lexicon Pharmaceuticals, Inc.	150,000	-
Medtronic	1,647,349	370,500
Merck Sharp & Dohme LLC	784,000	250,000
Novartis	7,716,663	7,320,133
Novo Nordisk, Inc.	2,392,040	-
Pfizer	2,139,158	-
Phlow	50,000	-
Regeneron Pharmaceuticals, Inc.	80,000	75,000
Sage Therapeutics	150,000	150,000
Sanofi	846,786	225,000
Schiller Americas, Inc.	84,136	-
Siemens Industry, Inc.	92,500	10,000
Stryker Instruments	35,890	40,000
Verily (Google Life Science LLC)	2,904,087	-
Zoll Medical Corporation	27,909	190,000
Totals	41,980,787	26,537,269

NOTE: (1) Includes all cash received from corporate contributions greater than \$50,000. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2015-2016 through fiscal year 2022-2023.